Consider the Benefits of New Meds to Prevent Chemo-Induced Nausea and Vomiting

March 2018

You'll see more players join the crowded field of neurokinin-1 antagonists for chemotherapy-induced nausea and vomiting (CINV).

IV aprepitant (Cinvanti, sin-VAHN-tee) and IV rolapitant (Varubi, vuh-ROO-bee) will join IV fosaprepitant (Emend). There are also 3 ORAL meds...aprepitant (Emend, etc), rolapitant (Varubi), and netupitant combined with the 5-HT3 antagonist palonosetron (Akynzeo).

Expect neurokinin-1 antagonists to be included in HIGHLY and some MODERATELY emetogenic chemotherapy protocols to prevent CINV...in addition to a 5-HT3 antagonist (ondansetron, etc), dexamethasone, and possibly olanzapine (Zyprexa, etc).

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote